We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+15.5%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.94B
AUM Growth
+$354M
Cap. Flow
+$71.5M
Cap. Flow %
2.43%
Top 10 Hldgs %
43.94%
Holding
91
New
27
Increased
20
Reduced
25
Closed
12
Avg Time Held
0.9 years
Top 10 Avg Time Held
1.1 years
Top 20 Avg Time Held
0.9 years

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$85.5M
2
QURE icon
uniQure
QURE
+$52M
3
LH icon
Labcorp
LH
+$50.7M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$46.9M
5
IFRX icon
InflaRx
IFRX
+$40.6M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$78.7M
2
PBYI icon
Puma Biotechnology
PBYI
+$74.6M
3
PEN icon
Penumbra
PEN
+$67.6M
4
ABT icon
Abbott
ABT
+$39.2M
5
RGNX icon
Regenxbio
RGNX
+$27.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.2%
2 Miscellaneous 1.77%
3 Financials 1.03%
4 Technology 0%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARRY icon
1
DELISTED
Array Biopharma Inc
ARRY
$268M 9.11%
15,978,580
-1,245,848
-7% -$19.8M
2013 Q2
20 quarters
FOLD icon
2
DELISTED
Amicus Therapeutics
FOLD
$164M 5.58%
10,511,732
-226,926
-2% -$3.43M
2013 Q2
20 quarters
ATRA icon
3
Atara Biotherapeutics
ATRA
$96M
$152M 5.15%
165,065
-4,376
-3% -$4.7M
2014 Q4
14 quarters
IMGN icon
4
DELISTED
Immunogen Inc
IMGN
$120M 4.07%
12,315,942
+2,613,460
+27% +$27.6M
2017 Q1
5 quarters
XNCR icon
5
Xencor
XNCR
$1.74B
$116M 3.96%
3,147,043
-57,300
-2% -$1.97M
2016 Q4
6 quarters
RGNX icon
6
Regenxbio
RGNX
$454M
$112M 3.81%
1,561,175
-569,797
-27% -$27.2M
2017 Q1
5 quarters
ALDR
7
DELISTED
Alder Biopharmaceuticals
ALDR
$103M 3.49%
6,505,766
– –
2016 Q3
7 quarters
WCG
8
DELISTED
Wellcare Health Plans, Inc.
WCG
$87.4M 2.97%
355,009
+12,700
+4% +$2.77M
2017 Q4
2 quarters
WVE icon
9
Wave Life Sciences
WVE
$609M
$85.9M 2.92%
2,244,507
+6,900
+0.3% +$297K
2015 Q4
10 quarters
BOLD icon
10
DELISTED
Audentes Therapeutics, Inc
BOLD
$85.2M 2.89%
2,228,656
+920,130
+70% +$34.1M
2016 Q3
7 quarters
CLVS
11
DELISTED
Clovis Oncology, Inc.
CLVS
$80M 2.72%
+1,758,600
New +$85.5M
2018 Q2
0 quarters
FATE icon
12
Fate Therapeutics
FATE
$232M
$75.5M 2.56%
6,655,962
– –
2015 Q2
12 quarters
IFRX icon
13
InflaRx
IFRX
$218M
$65.4M 2.22%
2,027,700
+1,176,600
+138% +$40.6M
2017 Q4
2 quarters
CNC icon
14
Centene
CNC
$34.7B
$62.6M 2.13%
1,015,970
-103,630
-9% -$5.98M
2017 Q2
4 quarters
QURE icon
15
uniQure
QURE
$1.45B
$61.4M 2.09%
+1,624,400
New +$52M
2018 Q2
0 quarters
ALXN
16
DELISTED
Alexion Pharmaceuticals
ALXN
$60.7M 2.06%
489,300
+84,500
+21% +$9.88M
2018 Q1
1 quarter
LIVN icon
17
LivaNova
LIVN
$4.19B
$59.9M 2.03%
599,788
+81,500
+16% +$7.4M
2017 Q2
4 quarters
DCPH icon
18
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$58.1M 1.97%
1,477,080
+655,800
+80% +$19.3M
2017 Q3
3 quarters
ARGX icon
19
argenx
ARGX
$51.5B
$55.8M 1.9%
673,300
+434,700
+182% +$38.9M
2017 Q4
2 quarters
ICUI icon
20
ICU Medical
ICUI
$4.07B
$54.1M 1.84%
184,172
-9,300
-5% -$2.54M
2017 Q1
5 quarters
LH icon
21
Labcorp
LH
$25.7B
$51.8M 1.76%
+335,698
New +$50.7M
2018 Q2
0 quarters
INSM icon
22
Insmed
INSM
$21.4B
$48.1M 1.63%
2,033,492
-132,870
-6% -$3.42M
2017 Q2
4 quarters
SYNH
23
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$46M 1.56%
981,673
-544,431
-36% -$22.5M
2017 Q1
5 quarters
XERS icon
24
Xeris Biopharma Holdings
XERS
$1.78B
$45.8M 1.56%
+2,412,642
New +$46.9M
2018 Q2
0 quarters
BLUE icon
25
DELISTED
bluebird bio
BLUE
$42.1M 1.43%
20,728
+108
+0.5% +$246K
2017 Q4
2 quarters
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2018 Portfolio in Review

As of Q2 2018, Redmile Group held 91 positions worth $2.94B, up 14% from $2.59B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Redmile Group's Q2 2018 filing shows 27 new, 20 increased, 25 reduced and 12 closed positions. Its largest new stake was Clovis Oncology, Inc.: 1,758,600 shares worth $80M. The largest sale was AveXis, Inc. Common Stock, an estimated $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q2 2018 buy was Clovis Oncology, Inc.: 1,758,600 shares worth $80M.
  • Redmile Group added most to InflaRx in Q2 2018, an estimated $40.6M increase.
  • Redmile Group's biggest Q2 2018 reduction was Penumbra, cutting an estimated $67.6M.
  • Redmile Group fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $78.7M.
  • Redmile Group's ten largest holdings make up 44% of its $2.94B portfolio in Q2 2018.
  • Redmile Group opened 27 new positions and closed 12 in Q2 2018.
  • Redmile Group's portfolio value rose 14% quarter-over-quarter to $2.94B.

Based on Redmile Group's 13F filing for Q2 2018, filed 14 Aug 2018.